Candel Therapeutics, Inc.
CADLCandel Therapeutics is a clinical-stage biopharmaceutical company developing off-the-shelf viral immunotherapies designed to elicit individualized, systemic anti-tumor immune responses.
Earnings
Next report
Aug 13, 2026 (In 2 weeks)Valuation & ratios
Competitors
By market cap
By net margin
Profile
Candel Therapeutics is a clinical-stage biopharmaceutical company developing off-the-shelf viral immunotherapies designed to elicit individualized, systemic anti-tumor immune responses. The company leverages proprietary adenovirus and herpes simplex virus (HSV) platforms to engineer viruses that induce immunogenic cell death and create pro-inflammatory microenvironments at tumor sites. Their core value proposition lies in converting immunologically "cold" tumors into "hot" tumors to improve patient outcomes across various solid tumor indications.
A clinical-stage innovator in viral immunotherapy with a lead candidate (aglatimagene) that has met primary endpoints in a Phase 3 trial for localized prostate cancer.
Questions, answered.
- What is Candel Therapeutics, Inc.'s market cap?
- Candel Therapeutics, Inc. (CADL) has a market capitalization of $729.8M and trades on NASDAQ.
- Who are Candel Therapeutics, Inc.'s competitors?
- Candel Therapeutics, Inc.'s key competitors include CG Oncology, Inc., Replimune Group, Inc., Amgen Inc., and others. These companies compete in similar markets and product categories.
- Who does Candel Therapeutics, Inc. partner with?
- Candel Therapeutics, Inc.'s notable partners include RTW Investments, LP, Mass General Brigham, Periphagen, and others.
- Where is Candel Therapeutics, Inc. headquartered?
- Candel Therapeutics, Inc. is headquartered in United States of America and employs approximately 42 people. It has been publicly traded since 2021.